Support of Central Spinal Fluid Biomarker Study–ADNI

2008

Cure Alzheimer’s Fund is part of a funding consortium supporting collaborative biomarker investigation of the elevation of tau and decreased concentrations of Amyloid beta 42 in the Central Spinal Fluid as evidence of the presence of the Alzheimer’s disease pathology.

Biomarkers/Diagnostics/Studies of Risk & Resilience Foundational John Trojanowski Leslie Shaw

Consortium to Infer Regulatory Circuits and Uncover Innovative Therapeutic Strategies—Production Group

Christina Lill, Lars Bertram, | 2020

Personalized Disease Prediction for Alzheimer’s Disease Using Proteome Profiling: The EPIC4AD Study

Liisa Galea, | 2020

Sex Matters: Understanding the Influence of Sex and Apolipoprotein E (APOE) Genotype on Hippocampal Plasticity and Cognition

Bradley Hyman, | 2020

Creation of a Fibroblast/iPS Cell Bank to Facilitate Peripheral/Brain Comparisons, and Allow Molecular Investigations into Molecular Mechanisms Underlying Differences in Disease Aggressiveness

Paola Bovolenta, Pilar Esteve, | 2020

SFRP1 as a Therapeutic Target and Diagnostic/Prognostic Factor in Alzheimer’s Disease

Krista L. Moulder, | 2020

Characterization of Alzheimer’s Disease Molecular Biomarker Profiles Throughout the Pathobiological Continuum

Shirley Wray,

An Innovative Study of the Pupil Light Reflex in Alzheimer’s Disease

Alejandra Camacho-Soto, Brad Racette, Susan Searles Nielsen, | 2019

Harnessing Big Data to Understand Alzheimer’s Disease Risk